Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. (Nasdaq: SSII) files reports and disclosures with the U.S. Securities and Exchange Commission as a registrant with common stock listed on The Nasdaq Stock Market LLC. These SEC filings provide detailed information about the company’s operations in surgical robotics, including its SSi Mantra surgical robotic system and SSi Mudra surgical instruments.
On this page, you can review SSII’s periodic and current reports, such as Form 10-Q quarterly reports and Form 8-K current reports. In its filings and related press releases, SS Innovations has discussed revenue from system sales, instrument sales, warranty sales, and lease income, as well as information about installations of the SSi Mantra system and the cumulative number of surgeries performed. Filings also reference clinical and regulatory milestones, including a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and plans for a 510(k) premarket notification to the U.S. Food and Drug Administration.
SS Innovations’ Form 8-K filings frequently incorporate press releases as exhibits, covering topics such as financial results, telesurgery achievements using the SSi Mantra and the SSi Mantra Tele Surgeon Console, executive appointments, and participation in investor conferences. These documents also confirm that the company’s common stock trades under the symbol SSII and that it is incorporated in Florida with principal executive offices in Gurugram, Haryana, India.
Stock Titan’s SEC filings page for SSII is designed to surface these regulatory documents alongside AI-powered summaries that explain key points in plain language. Users can quickly scan new 8-Ks, 10-Qs, and other filings, and identify disclosures related to revenue composition, operating performance, regulatory progress for the SSi Mantra system, and other material events affecting SS Innovations International Inc.
SS Innovations International, Inc. (SSII) reported an insider transaction by a director and officer serving as COO - Americas. On 10/08/2025, the insider reported a transaction in common stock coded "G," indicating a gift of 3,300 shares at a price of $0.00 per share. After this transaction, the insider beneficially owns 7,863,588 shares of SSII common stock in direct ownership. No derivative securities transactions were reported.
SS Innovations International (SSII) reported an insider transaction by Chairman and CEO Sudhir Srivastava. On 11/05/2025, he reported a code G gift of 30,000 shares of common stock at $0. Following the transaction, he beneficially owns 112,553,014 shares indirectly through Sushruta Pvt. Ltd.
Srivastava is listed as a Director and 10% Owner, and the shares are held of record by an entity he controls.
SS Innovations International, Inc. (SSII) furnished an updated November 2025 Company Presentation under Item 7.01 (Regulation FD Disclosure). The presentation is attached as Exhibit 99.1.
The materials are deemed “furnished,” not “filed,” which limits their applicability under Section 18 of the Exchange Act and they are not incorporated by reference into other filings. The notice includes customary forward‑looking statements language, highlighting that actual results may differ due to risks described in the company’s periodic reports.
SS Innovations International (SSII) reported a technology milestone. The company announced the successful completion of the first telesurgery performed using its SSi Mantra Tele Surgeon Console. The system is a compact, self-contained, chair-based version of the larger SSi Mantra command center, designed for portability, smaller spaces, and telesurgery from varied settings, including physician offices.
The announcement was made on November 6, 2025, and a detailed press release was furnished as Exhibit 99.1.
SS Innovations International (SSII) furnished a press release discussing results of operations for the three and nine month periods ended September 30, 2025. The company made the disclosure under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), and attached the press release as Exhibit 99.1.
The information in Items 2.02 and 7.01, and Exhibit 99.1, is deemed “furnished” rather than “filed,” and is not subject to Section 18 liabilities or incorporated by reference into other filings.
SS Innovations International (SSII) filed its quarterly report and reported strong top-line growth with continued losses. Q3 revenue was $12.83M, up from $4.39M a year ago, driven by system sales. Gross profit rose to $6.16M from $2.32M. The company posted a Q3 net loss of $3.72M and a year‑to‑date net loss of $9.66M, an improvement from $17.23M in the prior‑year period.
As of September 30, 2025, total cash, cash equivalents and restricted cash were $12.04M; current cash and cash equivalents were $5.68M. Working capital showed a surplus of $27.24M. Operating cash outflow was $17.02M year‑to‑date, partly offset by $24.79M of net financing inflows, including issuance of $28.0M of one‑year 7% convertible notes and subsequent conversions totaling 21.86M shares. Inventory increased to $20.04M from $10.21M to support demand.
The company disclosed “substantial doubt” about its ability to continue as a going concern, citing ongoing losses and reliance on related‑party funding even after its April 2025 Nasdaq uplisting. During Q3, it sold 28 surgical robotic systems (55 year‑to‑date). Revenue was concentrated in India, which represented 94% of Q3 sales.
SS Innovations International (SSII) announced management participation in two investor conferences. The company will join the UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 11, 2025, and the Stifel 2025 Healthcare Conference in New York, NY on November 12, 2025. The Stifel event includes a group presentation at 4:40 p.m. Eastern Time.
A live webcast and replay of the Stifel presentation will be available on the company’s website at https://ssinnovations.com/investor-overview/. The disclosure is provided under Item 7.01 (Regulation FD) and is deemed “furnished,” not “filed.”
SS Innovations International (SSII) furnished an updated October 2025 Company Presentation under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1 and is intended for communications with shareholders and the investment community.
The information is deemed “furnished” rather than “filed,” meaning it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings. The report also includes standard forward‑looking statements cautionary language.
Amar Naveen Kumar is reported as an officer (CFO) and director of SS Innovations International, Inc. (SSII). The Form 3 shows no beneficial ownership of the issuer's common stock and no derivative holdings are disclosed. The filing provides the reporting person's address in Fort Lauderdale, FL and includes the required signature attestation.
SS Innovations International, Inc. reported that it has successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. The company also stated that it anticipates submitting a 510(k) premarket notification to the U.S. Food and Drug Administration for SSi Mantra for multiple specialty indications in the fourth quarter of 2025. These steps mark progress in the company’s effort to bring its surgical robotic system to the U.S. market, although regulatory clearance has not yet been obtained.